Large-scale association analysis identifies new risk loci for coronary artery disease. by C. A.  R. et al.
Nature GeNetics  VOLUME 45 | NUMBER 1 | JANUARY 2013 25
Coronary artery disease and its main complication, myocardial infarc-
tion, is the leading cause of death worldwide. Although, epidemio-
logical studies have identified many risk factors for CAD, including 
plasma lipid concentrations, blood pressure, smoking, diabetes and 
markers of inflammation, a causal role has been proven only for 
some (for example, low-density lipoprotein (LDL) cholesterol and 
blood pressure), primarily through randomized clinical trials of drug 
therapy directed at the risk factor1. Twin and family studies have 
documented that a significant proportion (40–50%) of susceptibility 
to CAD is heritable (for a review, see ref. 2). Because genotypes are 
not confounded by environmental exposures, genetic analysis has the 
potential to define which risk factors are indeed causal and to identify 
pathways and therapeutic targets3,4. To date, genome-wide association 
studies (GWAS) have collectively reported a total of 31 loci, associ-
ated with CAD risk at genome-wide significance (P < 5 × 10−8)5–13. 
However, variants at these loci explain less than 10% of the heritability 
of CAD. One likely reason for this is that, given the polygenic nature 
of complex traits and the relatively small observed effect sizes of the 
loci identified, many genuinely associated variants do not reach the 
stringent P-value threshold for genome-wide significance. Indeed, 
there is increasing evidence that the genetic architecture of common 
traits involves a large number of causative alleles with very small 
effects14. Addressing this will require the discovery of additional loci 
while leveraging large-scale genomic data to identify the molecular 
pathways underlying the pathogenesis of CAD. Such discovery is facil-
itated by building molecular networks, on the basis of DNA, RNA and 
protein interactions, which have nodes of known biological function 
that also show evidence of association with risk variants for CAD and 
related metabolic traits.
In the largest GWAS meta-analysis of CAD undertaken to date 
by the Coronary ARtery DIsease Genome-wide Replication and 
Meta-analysis (CARDIoGRAM) Consortium5, which involved 22,233 
cases and 64,762 controls, in addition to loci reported at genome-wide 
 significance, a linkage disequilibrium (LD)-pruned set of 6,222 vari-
ants achieved a nominal association P value of less than 0.01. Here, 
we test these 6,222 SNPs in a meta-analysis of over 190,000 individuals, 
with the primary aim of identifying additional susceptibility loci for 
CAD. To this end, we used the Metabochip array15, which is a custom 
iSELECT chip (Illumina) containing 196,725 SNPs, designed to 
(i) follow-up putative associations in several cardiometabolic traits, 
including CAD, and (ii) fine map confirmed loci for these traits. 
All SNPs on the array with data in the CARDIoGRAM study were 
considered for analysis (79,138 SNPs, of which 6,222 were the repli-
cation SNPs and 20,876 were fine-mapping SNPs in the 22 CAD sus-
ceptibility loci identified at the time at which the array was designed; 
the remaining SNPs were submitted by the other consortia contri-
buting to the Metabochip array15). In addition, we assess whether the 
genome-wide significant CAD risk alleles act through traditional risk 
factors by considering the available large GWAS for these traits16–20. 
Finally, we identify a broader set of SNPs passing a conservative FDR 
threshold for association with CAD and use this set to undertake 
network analysis to find key biological pathways underlying the 
pathogenesis of CAD.
RESULTS
Study design
We expanded the CARDIoGRAM discovery data set (22,233 cases and 
64,762 controls5, stage 1) with 34 additional CAD sample collections 
(stage 2) of European or south Asian descent comprising 41,513 cases 
and 65,919 controls (study descriptions and sample characteristics are 
given in Supplementary Tables 1a and 2a, respectively) and under-
took a 2-stage meta-analysis to test SNPs on the Metabochip array 
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for disease association in a total of 63,746 cases and 130,681 controls. 
A further set of 3,630 cases and 11,983 controls from 4 independent stud-
ies was used for replication of SNPs that reached 5 × 10−8 < P < 1 × 10−6 
in combined stage 1 and 2 analysis (stage 3; Supplementary 
Tables 1b and 2b). An overview of the study design is provided in 
Supplementary Figure 1. Cases were selected for inclusion following 
the standard criteria for CAD and myocardial infarction used in the 
CARDIoGRAM study5 (details for the stage 2 and 3 cohorts are given 
in Supplementary Table 2). Collections were typed with either the 
Metabochip array (60% of samples) or provided GWAS data imputed 
using HapMap (Supplementary Table 3). We applied standard quality 
control criteria to each study and corrected for population stratifica-
tion if λGC was ≥1.05 (estimated for samples typed on the Metabochip 
using 4,310 SNPs associated with long QT syndrome and located at 
least 5 Mb away from established CAD risk loci; Online Methods). 
Case-control association analyses were adjusted for sex and age. For 
the 79,138 SNPs on the Metabochip with both stage 1 and 2 data, 
we combined (2-sided) P values from stage 1 with their respective 
(1-sided) P values for stage 2 using Fisher’s method (Online Methods). 
In stage 3, we validated SNPs at 5 × 10−8 < P < 1 × 10−6 and com-
bined evidence across all stages (1– 3) using a sample size–weighted 
meta-analysis.
Genome-wide significant loci
We first examined the 30 CAD risk loci previously reported in individ-
uals of European ancestry at genome-wide significance (the ADTRP 
(C6orf105) locus has been reported only in Chinese)12 in the stage 
2 samples. For the 26 loci in which we could test the known lead SNP or 
a suitable proxy (r2 > 0.8), we found highly significant associations in 
the stage 2 samples (Table 1). Notably, in four of these loci (CDKN2B-
AS1, COL4A2, CXCL12 and APOE), we detected additional SNPs not 
in LD (r2 < 0.5) with the lead SNP, which also reached genome-wide 
significance and were conditionally independent when analyzed with 
GCTA software21. The additional SNP in the APOE locus, rs445925 
(P = 9.42 × 10−11; r2 = 0.015 with rs207560 in 1000 Genomes Project 
data), is located near APOC1, a gene previously suggested to confer 
risk for CAD22. The r2 value between rs445925 (P = 9.42 × 10−11; 
n = 31 studies) and rs7412 (P = 8.86 × 10−4; n = 21 studies), which 
tags the APOE e2 allele,is 0.588. The LIPA locus also harbors a strong 
independent signal, which, however, did not reach genome-wide sig-
nificance. Findings for the strongest associated variant available on 
the Metabochip for the other four loci (MIA3, 7q22, ZNF259-APOA5-
APOA1 and ADAMTS7) for which we did not have a good proxy for 
the previously reported lead SNP are also given (Table 1). Notably, 
for ADAMTS7, rs7173743 (r2 = 0.38 with rs3825807, the published 
lead SNP) also achieved genome-wide significance.
We next examined the association of the 6,222 SNPs with P < 0.01 
in CARDIoGRAM (we excluded SNPs in all loci listed in Table 1). 
Distribution of the absolute z scores for these SNPs in the stage 2 
samples showed strong enrichment in positive scores corresponding 
to SNPs with directionally consistent signals between stages 1 and 2 
under the null distribution, which is defined by mean = 0 and s.d. = 1 
(4,260 SNPs observed versus 3,111 SNPs expected; binomial 2-sided 
P = 7.5 × 10−187) (Supplementary Fig. 2). In total, 19 loci showed 
association at P < 1 × 10−6 in the combined stage 1 and 2 analysis, with 
13 of them reaching genome-wide significance, namely IL6R, APOB, 
VAMP5-VAMP8-GGCX, SLC22A4-SLC22A5, ZEB2-AC074093.1, 
GUCY1A3, KCNK5, LPL, PLG, TRIB1, ABCG5-ABCG8, FURIN-FES 
and FLT1 (Table 2; Forest and regional association plots are given in 
Supplementary Figs. 3 and 4, respectively). The 6 loci with associa-
tions not reaching P < 5 × 10−8 were further validated (stage 3) in 4 
independent studies (3,630 cases and 11,983 controls; Supplementary 
Table 1b). Two loci, EDNRA and HDAC9 replicated at P < 0.05 and 
reached genome-wide significance in a combined analysis of stages 
1–3 (Table 2); findings for those SNPs not meeting the above criteria 
are shown in Supplementary Table 4.
Of the newly associated loci reaching genome-wide significance, 
TRIB1 and ABCG5-ABCG8 were recently reported to reach study-
wide significance (P < 3 × 10−6) in a large candidate gene (IBC array) 
study of CAD13. The same study reported rs2706399 in the IL5 locus, 
which is located 200,349 bp away from the SNP we detected in the 
SLC22A4-SLC22A5 locus (rs273909; Table 2). Although located in the 
same recombination interval, these SNPs are not in LD (r2 = 0.02), and 
conditional analysis in a subset of 85,136 samples (up to19,200 cases) 
suggested that the 2 signals are conditionally independent; when con-
ditioning on rs2706399 (IL5 locus), the P value for rs273909 (SLC22A4 
locus) was 5.54 × 10−3 (1.33 × 10−3 initially), whereas the converse con-
ditioning gave a P value of 3.34 × 10−2 for rs2706399 (IL5; 7.55 × 10−3 
initially). We also detected a second signal in the FES locus (rs2521501; 
P = 1.31 × 10−9); conditional analysis with rs17514846 and rs2521501 
(r2 = 0.43 in 1000 Genomes Project data) showed the two signals not 
only to be independent but to also increase in strength upon condition-
ing (rs17514846 associated at P = 1.07 × 10−25 when conditioned on 
rs2521501; conversely, the P value for rs2521501 was 9.24 × 10−26).
Subgroup analyses
Genetic risk of CAD could vary by age and gender and could also 
specifically influence the risk of its main adverse outcome, myocardial 
infarction23. We therefore undertook exploratory association analyses in 
subgroups partitioned by either gender, age at event (with individuals of 
<50 years of age being defined as young cases) or history of myocardial 
infarction (Online Methods). For the 46 genome-wide significant CAD 
risk loci, we observed no trend for higher odds ratios (ORs) in any of 
the subgroup analyses (Supplementary Table 5). However, one new 
locus reached genome-wide significance in males and in young CAD 
cases (rs16986953; P = 1.89 × 10−8 and 1.67 × 10−8, respectively), which 
is located in a gene desert (with nearest transcript AK097927), 1.3 Mb 
away from the APOB gene. Interaction analysis conducted in a subset 
of studies (n = 12) where we had individual-level data provided sug-
gestive evidence of an association with age (P = 0.033) but not with sex 
(P = 0.708); further studies are required to confirm this finding.
Wider Metabochip content
In addition to SNPs provided by the CARDIoGRAM Consortium, 
the Metabochip array contains a further 113,248 SNPs submitted for 
a range of cardiometabolic traits15 other than CAD itself (associated at 
P > 0.01 with CAD in CARDIoGRAM samples or not tested). For these 
SNPs, we did not detect any new locus reaching genome-wide signi-
ficance in our data set (including stage 1 and 3 data, when available). 
In total, therefore, we discovered 15 newly associated loci at genome-wide 
significance, increasing the total number of genome-wide significant 
loci to 45 in individuals of European and south Asian ancestry.
Localizing candidate CAD genes
To identify potential causal CAD-associated genes at the 15 new sus-
ceptibility loci identified in our study, we first analyzed genome-wide 
expression quantitative trait locus (eQTL) data in multiple tissues 
(circulating monocytes, liver, fat, skin, omentum, aortic media and 
adventitia, mammary artery and lymphoblastoid cell lines (LCLs)). 
We found that the lead SNP or a proxy in high LD (r2 ≥ 0.8) in three 
of the new loci was associated in cis with variable expression levels of 
the GGCX-VAMP8, PLG and FES genes (Supplementary Table 6). 
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We then assessed allele-specific expression data in monocytes, fibro-
blasts and LCLs and found three loci where the lead SNP was associ-
ated with an imbalance in expression of either LPL, GGCX or FES; 
IL6R showed some evidence of allele-specific expression in the fibro-
blast sample (Supplementary Table 6). Finally, we examined the new 
CAD risk loci for genes with relevant disease trait associations in 
mouse knockout models; six loci harbor a gene for which a mouse 
knockout model has a relevant cardiovascular phenotype, namely 
ABCG8, APOB, GUCY1A3, PLG, LPL and FES (Supplementary 
Table 7). PLG is adjacent to LPA, and, although the PLG risk variant 
rs4252120[T] was strongly associated with elevated Lp(a) lipoprotein 
levels (P = 5 × 10−24) in 3,698 PROCARDIS cases, it was associated 
with CAD independent of the LPA-linked variant at rs3798220. 
A detailed discussion of the genes in each locus is provided in the 
Supplementary Note. Of the 30 previously reported CAD suscep-
tibility loci in individuals of European and south Asian ancestry, 
mouse knockout models for the candidate genes PEMT, APOE, LDLR, 
COL4A1, LIPA, APOA1-APOA5, PPAP2B and PCSK9 also show pheno-
typic characteristics directly relevant to disease (Supplementary 
Table 7). In total, approximately a third of the 45 CAD loci contain a 
known functionally relevant candidate gene.
Overlap with traditional risk factors
We assessed both the known and new CAD susceptibility loci for 
overlap of associations with a number of relevant traits for which 
summary statistics have been made available: lipid levels (GLGC)16, 
blood pressure (ICBPG)17, diabetes (DIAGRAM)18, glucometabolic 
traits (fasting insulin and fasting glucose concentrations, HOMA-B 
table 1 Association findings for known cAD susceptibility loci
Known locia Published lead SNP or proxy
New SNP  
(r2 with lead SNP) Chr.
Effect/non-effect  
allele (frequency) Stage 2 OR Stage 2 P Combined P Combined OR
SORT1b rs602633  
(tagging rs599839; r 2 = 1.00)
1 C/A (0.77) 1.13 2.19 × 10−18 1.47 × 10−25 1.12
PCSK9 rs11206510 1 T/C (0.84) 1.04 5.09 × 10–3 1.79 × 10–5 1.06
WDR12 rs6725887 2 C/T (0.11) 1.10 5.29 × 10–8 1.16 × 10–15 1.12
MRAS rs9818870 3 T/C (0.14) 1.05 1.83 × 10–3 2.62 × 10–9 1.07
TCF21 rs12190287 6 C/G (0.59) 1.04 6.48 × 10–4 4.94 × 10–13 1.07
SLC22A3-LPAL2-LPA rs3798220 6 C/T (0.01) 1.28 4.90 × 10–5 N/A N/A
rs2048327 (0.03) 6 G/A (0.35) 1.05 1.09 × 10–5 6.86 × 10–11 1.06
ZC3HC1 rs11556924 7 C/T (0.65) 1.08 1.45 × 10–9 6.74 × 10–17 1.09
CDKN2BAS1 rs1333049 9 C/G (0.47) 1.21 1.08 × 10–34 1.39 × 10–52 1.23
rs3217992 (0.50) 9 A/G (0.38) 1.14 7.27 × 10–32 7.75 × 10–57 1.16
ABO rs579459 9 C/T (0.21) 1.04 2.13 × 10–2 2.66 × 10–8 1.07
CYP17A1-CNNM2-NT5C2 rs12413409 10 G/A (0.89) 1.08 4.12 × 10–3 6.26 × 10–8 1.10
KIAA1462 rs2505083 10 C/T (0.42) 1.06 2.82 × 10–7 1.35 × 10–11 1.06
PDGFD rs974819 11 A/G (0.29) 1.08 2.03 × 10–9 3.55 × 10–11 1.07
SH2B3 rs3184504 12 T/C (0.40) 1.07 6.13 × 10–7 5.44 × 10–11 1.07
COL4A1-COL4A2 rs4773144 13 G/A (0.42) 1.06 2.34 × 10–6 1.43 × 10–11 1.07
rs9515203 (0.01) 13 T/C (0.74) 1.08 1.13 × 10–8 5.85 × 10–12 1.08
HHIPL1 rs2895811 14 C/T (0.43) 1.04 1.18 × 10–4 4.08 × 10–10 1.06
RAI1-PEMT-RASD1 rs12936587 17 G/A (0.59) 1.04 2.06 × 10–4 1.24 × 10–9 1.06
LDLR rs1122608 19 G/T (0.76) 1.06 3.72 × 10–6 6.33 × 10–14 1.10
Gene desert (KCNE2) rs9982601 21 T/C (0.13) 1.10 8.69 × 10–9 7.67 × 10–17 1.13
PPAP2B rs17114036 1 A/G (0.91) 1.09 2.68 × 10–5 5.80 × 10–12 1.11
ANKS1A rs12205331 (tagging 
rs17609940; r 2 = 0.85)
6 C/T (0.81) 1.01 4.36 × 10–1 4.18 × 10–5 1.04
PHACTR1 rs9369640 (tagging rs12526453; 
r 2 = 0.90)
6 A/C (0.65) 1.09 1.11 × 10–12 7.53 × 10–22 1.09
CXCL12 rs501120 10 A/G (0.83) 1.06 7.13 × 10–5 1.79 × 10–9 1.07
rs2047009 (0.05) 10 C/A (0.48) 1.05 9.66 × 10–6 1.59 × 10–9 1.05
LIPA rs2246833  
(tagging rs1412444; r 2 = 0.98)
10 T/C (0.38) 1.04 2.76 × 10–2 9.49 × 10–6 1.06
rs11203042 (0.39) 10 T/C (0.44) 1.03 9.86 × 10–3 6.08 × 10–6 1.04
UBE2Z rs15563 (tagging rs46522;  
r 2 = 0.93)
17 C/T (0.52) 1.01 2.44 × 10–1 9.37 × 10–6 1.04
SMG6 rs2281727  
(tagging rs216172; r2 = 0.96)
17 C/T (0.36) 1.04 8.46 × 10–4 7.83 × 10–9 1.05
ApoE-ApoC1 rs2075650 19 G/A (0.14) 1.11 5.86 × 10–11 N/A N/A
rs445925 (0.03) 19 C/T (0.90) 1.13 8.76 × 10–9 N/A N/A
MIA3 N/A rs17464857 (0.18) 1 T/G (0.87) 1.02 1.56 × 10–1 6.06 × 10–5 1.05
7q22 N/A rs12539895 (0.64) 7 A/C (0.19) 1.02 4.00 × 10–2 5.33 × 10–4 1.08
ZNF259-APOA5-APOA1 N/A rs9326246 (0.63) 11 C/G (0.10) 1.04 2.90 × 10–2 1.51 × 10–7 1.09
ADAMTS7 N/A rs7173743 (0.38) 15 T/C (0.58) 1.06 2.46 × 10–7 6.74 × 10–13 1.07
Chr., chromosome.
aLocus C6orf105, which has been reported only in Chinese and has no good proxy SNP (Utah residents of Northern and Western European ancestry (CEU) or Han Chinese in Beijing, China 
(CHB)) on the Metabochip. The best available proxy is rs9348953 (r2 = 0.01), with combined P = 2.81 × 10–3. brs12740374, which was reported as a functional variant in this locus and has  
r2 = 0.895 with rs599839, has combined P = 8.25 × 10–18 (OR = 1.135) based on the random-effects model used (P in stage 2 alone was 6.48 × 10–21 under the fixed-effect model).
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(homeostatic model assessment-β score) and HOMA-IR (insulin 
resistance); MAGIC)19 and anthropometric traits (GIANT)20,24. 
After applying a Bonferroni correction for the 51 independent CAD- 
associated alleles tested (44 loci; no data available for rs16986953 and 
rs2521501), 12 loci showed evidence of association (P < 1 × 10−4) 
between the lead CAD risk SNP and 1 or more plasma lipid trait 
(total cholesterol, LDL cholesterol, high-density lipoprotein (HDL) 
cholesterol and triglyceride concentration) in the expected direction 
(the CAD risk allele was associated with higher total cholesterol, LDL 
cholesterol and triglyceride concentrations and lower HDL choles-
terol concentration). These lead SNPs were most strongly associated 
with LDL cholesterol concentration at eight loci (APOB, ABCG5-
ABCG8, PCSK9, SORT1, ABO, LDLR, APOE and LPA), with trig-
lyceride concentration at two loci (TRIB1 and the APOA5 cluster) 
and with HDL cholesterol concentration at one locus (ANKS1A). 
There was near-equivalent association for triglyceride and HDL 
cholesterol concentrations at one locus (LPL). All loci except LPA 
and ANKS1A showed genome-wide significance for association with 
a lipid trait. These results underscore the importance of LDL choles-
terol as a causal CAD risk factor (Supplementary Table 8). At the 
SH2B3 locus, the CAD risk allele for rs3184504 was associated with 
both lower LDL cholesterol (P = 1.73 × 10−9) and HDL cholesterol 
(P = 4.97 × 10−6) concentration; one likely explanation is the presence 
of independent variants for CAD and LDL cholesterol. Two known 
CAD risk loci (CYP17A1-NT5C2 and SH2B3) and two of the new 
CAD susceptibility loci (GUCY1A3 and FES) have previously been 
associated with systolic (SBP) and diastolic (DBP) blood pressure17. 
Significant evidence for association with DBP was also observed for 
ZC3HC1 (Supplementary Table 8). In contrast to the results for lipid 
concentration and blood pressure, there was no significant association 
of any of the loci tested with type 2 diabetes (T2D). Consistent with 
this observation, none of the assessed glucometabolic traits (fasting 
insulin and fasting glucose concentrations, HOMA-B and HOMA-IR) 
were related to these CAD variants (at the ANKS1A locus, it was not 
the CAD risk SNP that was associated with fasting insulin concentra-
tion and HOMA-IR). Suggestive associations (P < 1 × 10−4) with body 
mass index (BMI) and waist-hip ratio were observed in the CYP17A1-
CNNM2-NT5C2 and RAI1-PEMT-RASD1 loci, respectively.
Additional suggestive associations
The genome-wide significance threshold, P < 5 × 10−8, we used is 
the accepted criterion for reporting individual association signals, as 
for each experiment it controls the error rate among common vari-
ants to less than 5%. However, SNPs showing suggestive association 
with a phenotype but not meeting this genome-wide threshold are 
likely to include additional true positive signals in well-powered stud-
ies (Supplementary Fig. 1). Such SNPs may also be informative in 
predicting CAD risk and in constructing CAD-associated biological 
networks. To identify such variants, we undertook an FDR analysis to 
assess the proportion of false positive signals in a set of (nominally) 
significant SNPs25. The Metabochip array contains both SNPs with pri-
ors in terms of association to CAD (CARDIoGRAM study P < 0.01) and 
blocks of highly correlated SNPs in fine-mapping regions. Therefore, 
to normalize the distribution of SNPs considered for FDR analysis, 
we (i) removed all SNPs in the CAD fine-mapping regions and LD-
pruned (r2 < 0.2) SNPs in the non CAD fine-mapping regions and 
(ii) adjusted the combined P values of all SNPs with priors in stage 1 
(P < 0.01) using fixed-effect inverse variance–weighted meta- 
analysis P values for all other SNPs (Online Methods). In addition, 
we obtained 104 SNPs at an FDR threshold of 5% and LD threshold 
of r2 < 0.2 (Supplementary Table 9). The median OR for CAD for 
these SNPs was 1.054 (interquartile range of 0.0199) per risk allele 
(Supplementary Fig. 5).
On the basis of a heritability estimate of 40% for CAD, the combina-
tion of the known and newly associated SNPs within the 45 suscepti-
bility loci (Tables 1 and 2) explains approximately 6% of the additive 
genetic variance of CAD. The addition of the 104 SNPs from FDR ana-
lysis increased the fraction explained to 10.6% (Online Methods).
table 2 Additional loci showing genome-wide significant association with cAD
Stage 1 (18,014 
cases and 40,925 
controls)a
Stage 2 (40,365 
cases and 63,714 
controls)
Combined 
(stages 1  
and 2)
Stage 3 (5,055 
cases and 5,617 
controls)
Combined  
(stages 1–3)
SNP Chr. Nearest gene(s)
Effect/non-
effect allele 
(frequency) OR P OR P P OR P P
Biological 
relevanceb
New
rs4845625 1 IL6R T/C (0.47) 1.06 4.84 × 10–5 1.04 3.46 × 10–5 3.55 × 10–8 1.09 1.58 × 10–3 3.64 × 10–10 2
rs515135 2 APOB G/A (0.83) 1.07 8.63 × 10–4 1.08 2.17 × 10–8 4.80 × 10–10 1.03 4.02 × 10–1 2.56 × 10–10 1
rs2252641 2 ZEB2-AC074093.1 G/A (0.46) 1.06 1.37 × 10–5 1.04 1.27 × 10–4 3.66 × 10–8 1.00 9.54 × 10–1 5.30 × 10–8
rs1561198 2 VAMP5-VAMP8-GGCX A/G (0.45) 1.06 7.47 × 10–5 1.05 2.57 × 10–6 4.48 × 10–9 1.07 1.75 × 10–2 1.22 × 10–10 A,1
rs7692387 4 GUCY1A3 G/A (0.81) 1.08 1.04 × 10–5 1.06 1.89 × 10–5 4.57 × 10–9 1.13 5.47 × 10–4 2.65 × 10–11 1
rs273909 5 SLC22A4-SLC22A5 C/T (0.14) 1.07 3.24 × 10–3 1.09 2.00 × 10–7 1.43 × 10–8 1.11 2.43 × 10–2 9.62 × 10–10 A,1
rs10947789 6 KCNK5 T/C (0.76) 1.07 6.07 × 10–5 1.06 1.22 × 10–5 1.63 × 10–8 1.01 7.03 × 10–1 9.81 × 10–9 3
rs4252120 6 PLG T/C (0.73) 1.07 1.18 × 10–5 1.06 1.82 × 10–5 5.00 × 10–9 1.07 9.58 × 10–2 4.88 × 10–10 1
rs264 8 LPL G/A (0.86) 1.11 2.99 × 10–7 1.05 7.30 × 10–4 5.06 × 10–9 1.06 1.60 × 10–1 2.88 × 10–9 1
rs9319428 13 FLT1 A/G (0.32) 1.06 7.88 × 10–5 1.05 5.70 × 10–6 1.01 × 10–8 1.10 1.37 × 10–3 7.32 × 10–11 1
rs17514846 15 FURIN-FES A/C (0.44) 1.07 2.37 × 10–5 1.05 7.35 × 10–7 4.49 × 10–10 1.04 3.02 × 10–1 9.33 × 10–11 A,1
Previously reported at array-wide level of significance (P < 3 × 10−6)
Rs2954029 8 TRIB1 A/T (0.55) 1.06 2.79 × 10–5 1.04 7.75 × 10–5 4.53 × 10–8 1.05 8.56 × 10–2 4.75 × 10–9 4
Rs6544713 2 ABCG5-ABCG8 T/C (0.30) 1.06 2.22 × 10–4 1.06 1.57 × 10–7 8.72 × 10–10 0.96 3.56 × 10–1 2.12 × 10–9 1
New (stage 3 replication)
Rs1878406 4 EDNRA T/C (0.15) 1.10 2.37 × 10–6 1.06 3.54 × 10–3 1.65 × 10–7 1.09 2.01 × 10–2 2.54 × 10–8 1
Rs2023938 7 HDAC9 G/A (0.10) 1.08 6.81 × 10–4 1.07 5.25 × 10–5 6.49 × 10–7 1.13 4.09 × 10–2 4.94 × 10–8 1
aTotal sample sizes do not include the CHARGE sample sizes. bA, cis eQTL in LCLs; 1, mouse model available with cardiovascular phenotype; 2, mouse model has homeostatic and immune 
phenotypes; 3, mouse model has respiratory, nervous system, mortality, aging, growth and renal phenotypes; 4, mouse model has growth and immune phenotypes.
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Network analysis
In contrast to estimating heritability where we want to keep the false 
positive rate as low as possible, in network analysis, we want to maxi-
mize the representation of potential network nodes in the gene set 
used. Thus, to perform network analysis, we selected the top 222 SNPs 
defined by the FDR analysis (10% FDR; final P < 6.6 × 10−4) at an LD 
threshold of r2 ≤ 0.7 and assigned 239 candidate genes on the basis of 
either eQTL data or physical proximity (Supplementary Table 10).
We mapped 238 of the 239 genes in the Ingenuity Knowledge Base 
and considered 233 for network construction (Online Methods) on 
the basis of available data on interactions in humans, mice and/or rats 
(51 genes within the 46 genome-wide significant loci (set A) and 182 
genes within the loci selected at FDR < 10% (set B)). Including neigh-
boring genes, Ingenuity generated 9 networks comprising 553 nodes; 
these included 48 (94.1%) of the genes in set A and 156 (85.7%) of 
those in set B (Supplementary Table 10). We obtained 2 overlapping 
networks: ON1, which included networks 1, 2, 6 and 8, comprising 
the majority of genes in both sets (33 and 83 in sets A and B, respec-
tively), and ON2, which included networks 4 and 7 (Supplementary 
Table 10). The nine networks were strongly enriched for genes (query 
set) known to be involved in lipid metabolism (P = 1.48 × 10−9), 
cellular movement (blood and endothelial cells; P = 1.35 × 10−7) and 
processes such as tissue morphology (size and area of atherosclerotic 
lesion, quantity of leukocytes, macrophages and smooth muscle cells; 
P = 9.66 × 10−10) and immune cell trafficking (migration and adhe-
sion; P = 1.12 × 10−7). As a negative control in the network analysis, 
we used a set of 368 genes selected from the least significant SNPs 
in the FDR analysis; the resulting networks showed no significant 
enrichment in relevant molecular functions and process (results 
described in detail in the Supplementary Note).
We then assessed how genes in the networks overlap with canonical 
pathways in the Ingenuity database. The four most significant canonical 
pathways represented in these networks are shown in Figure 1a. 
The top three pathways, atherosclerosis signaling, liver X receptor 
(LXR)/retinoid X receptor (RXR) activation and farnesoid X receptor 
(FXR)/RXR activation, all harbor genes involved in lipid metabolism, 
including ten CAD risk loci (ABCG5-ABCG8, APOA1, APOA5, APOB, 
APOE, CXCL12, LDLR, LPA, LPL and PDGFD). This is in agreement 
with our finding that 12 CAD risk loci are associated with lipid levels 
at P < 1 × 10−4 (Supplementary Table 8). Notably, three of the top four 
pathways also contain genes involved in inflammation. In addition 
to the atherosclerosis signaling and LXR/RXR activation pathways, 
the acute phase response signaling (AAPRS) pathway, which includes 
four CAD risk loci (APOA1, MRAS, IL6R and PLG), is involved in 
inflammation and, more specifically, the rapid inflammatory response 
that is triggered, among other factors, by tissue injury. Genes from 
both the lipid metabolism and inflammation-related pathways map 
to all networks, except network 9, which harbors only two genes 
(Supplementary Table 10). As shown for overlapping network ON1 
(Supplementary Fig. 6), genes in lipid metabolism and inflamma-
tion are interconnected and include both CAD-associated loci reach-
ing genome-wide significance and candidate loci at FDR < 10%. Key 
interactions between CAD susceptibility genes (known, new and the 
FDR set) involved in lipid metabolism and inflammation are shown 
in Figure 1b; macrophages take up oxidized LDL (ox-LDL) through 
their cell surface scavenger receptors to form foam cells. Foam cells 
secrete proinflammatory cytokines, such as interleukin (IL)-1, IL-6 
and matrix metalloproteinases, which can amplify the local inflam-
matory response and stimulate smooth muscle cell proliferation and 
initial migration toward the lesion26. Regulation of collagen secre-
tion by smooth muscle cells in the extracellular matrix is regulated by 
matrix metalloproteinases. Reduction of collagen in the extracellular 
matrix will destabilize the plaque. Both COL4A1 and COL4A2 encode 
subunits of type IV collagen, which is the major structural component 
of basement membranes lining the inner surface of blood vessels. 
Metalloproteinases have a role in the maintenance of the extracellular 
matrix and remodeling, contributing to the transition of plaques from 
stable to vulnerable states (Fig. 1b).
Biological function P value
Atherosclerosis signaling 1.67 × 10–6
LXR/RXR activation 2.14 × 10–6
FXR/RXR activation 5.76 × 10–6
Acute phase response signaling 4.36 × 10–5
Canonical pathways
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Figure 1 Canonical pathway analysis.  
(a) The four most significant canonical  
pathways represented in networks 3, 5  
and 9, and overlapping networks ON1  
(includes networks 1, 2, 6 and 8) and ON2 (includes networks 4 and 7); all molecules are listed by network in supplementary table 10. (b) Schematic 
showing parts of the atherosclerosis signaling, LXR/RXR activation and acute phase response signaling canonical pathways (Ingenuity) that are involved 
in both lipid metabolism and inflammation. Genes in confirmed CAD susceptibility loci (including both previously and newly reported) and in loci 
showing suggestive association with an FDR of <10% are depicted as black and gray ovals, respectively. Other key genes are depicted as white ovals; 
notably, some of them, such as IL1F10-IL1B, STAT3 and HMGCR, have SNPs ranking in the top 1,000 in the FDR analysis. The process leading  
to myocardial infarction involves multiple cell types that are depicted in this schematic as a composite cell (large oval) and its nucleus (inner oval) 
in the extracellular space; the smooth muscle cell is shown separately (SMC; red oval), whereas the blue oval depicts cell types involved in the 
inflammatory response. 
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DISCUSSION
Here, we report the largest genetic study to date assessing the impact 
of common variation on CAD risk. On the basis of analyses involv-
ing 63,746 CAD cases and 130,681 controls, we identified 15 new 
risk alleles at genome-wide significance, bringing the total number 
of confirmed CAD susceptibility loci in individuals of European and 
south Asian ancestry to 45. We also identified a further set of 104 
likely independent (r2 < 0.2) SNPs associated at an FDR of 5% with 
ORs between 1.031 and 1.126 per risk allele. In total, we estimate that 
these variants explain approximately 10.6% of the additive genetic 
variance of CAD (although we note that this may be an overestimate, 
given that it was not obtained in an independent sample). Our data 
also support the presence of additional true signals among the tested 
common SNPs that are likely to further contribute in explaining 
heritability; for example, the P-value adjustment we applied in the 
FDR analysis penalized the replication SNPs.
Among the 45 loci in individuals of European and south Asian ancestry 
that were confirmed to be associated with CAD, we found that 12 were 
significantly associated with the concentrations of blood lipids (mainly 
with LDL cholesterol), and 5 were associated with blood pressure. These 
data support the known etiological relationships of plasma lipids and 
blood pressure with CAD. People with T2D seem to have a 1.5- to 
2-fold higher risk of CAD than those without diabetes27, but none of 
the 45 risk loci were associated with diabetes status or with continuous 
levels of various glucometabolic traits. We note that, for the binary 
variable of T2D status, inability to show associations with CAD risk 
loci may reflect limited statistical power. The temporal relationship 
for comorbidity with both diabetes and CAD is complex: individuals 
with CAD without diabetes at diagnosis often subsequently develop 
T2D28. Furthermore, despite clear benefits in preventing microvascular 
disease (for example, retinopathy and nephropathy), intensive glucose 
control in diabetics reduces the risk of cardiovascular disease relatively 
modestly29. However, before a final conclusion can be reached, as many 
cohorts contributing to this meta-analysis focused by design on early 
disease manifestation or excluded diabetic individuals, a formal test-
ing of the relationship of T2D and CAD in Mendelian randomization 
experiments will be necessary. To this end, the large genetic association 
data set on CAD assembled here will also facilitate testing of the causal 
relationship of other putative risk factors for CAD.
A desirable clinical goal is to integrate genetic information into 
a risk score for CAD in an attempt to provide improved predictive 
power over traditional risk factors in asymptomatic subjects, such 
that preventative measures, where available, can be more appropri-
ately targeted. Our findings provide an appropriate framework of 153 
CAD risk variants (at those established as susceptibility loci meeting 
the genome-wide significance threshold and additional suggestive 
loci with an FDR of <5%) for assessing a genetic risk score in well-
 powered prospective studies to determine whether they are sufficiently 
informative and independent predictors to have potential for use in 
day-to-day practice.
Allowing for inherent limitations in selecting likely candidate 
genes at each locus, our network analysis identified lipid metabo-
lism and inflammation as key biological pathways involved in the 
genetic pathogenesis of CAD. Indeed, there was significant crosstalk 
between the lipid metabolism and inflammation pathways identified 
(Fig. 1). The emergence of lipid metabolism as a key pathway provides 
a positive control for the network and pathway analysis. On the other 
hand, this analysis provides strong new evidence at the molecular 
level in support of the causal involvement of inflammatory mecha-
nisms in the pathogenesis of coronary atherosclerosis30. The role of 
inflammation in atherosclerosis is well documented in the literature26; 
for example, risk factors such as fat diet, smoking, hypertension, hyper-
glycemia, obesity and insulin resistance can trigger the expression 
of adhesion molecules (upregulated by atherogenic lipoproteins such 
as ox-LDL, very-low-density lipoprotein (VLDL) and Lp(a) lipopro-
tein) by endothelial cells, leading to the attachment of monocytes to 
the arterial wall. Although our analysis identified as significant the 
rapid inflammatory response pathway (mediated by NF-κB, MAPK 
and JAK-STAT signaling) that is primarily involved in innate immu-
nity, many of the effector pathways in innate and adaptive immunity 
are heavily overlapping, and both are likely to have a role in CAD 
pathogenesis26. The five CAD-related networks constitute a useful 
framework for further functional and mechanistic studies to eluci-
date the biological processes underlying CAD pathogenesis and to 
investigate gene-environment interactions.
URLs. QVALUE software for FDR analysis, http://genomics.princeton.
edu/storeylab/qvalue/; coronary heart disease statistics, http://www.bhf.
org.uk/publications/view-publication.aspx?ps=1002097; top 10 causes 
of death fact sheet 310, http://www.who.int/mediacentre/factsheets/
fs310/en/index.html; Uppsala Platform, http://molmed.medsci.uu.se/
SNP+SEQ+Technology+Platform/Genotyping.
METHODS
Methods and any associated references are available in the online 
version of the paper.
Accession codes. Summary statistics for the 79,138 SNPs 
considered in this study for association with CAD (SNPs with 
stage 1 and stage 2 data) are available at ftp://ftp.sanger.ac.uk/pub/
cardiogramplusc4d/.
Note: Supplementary information is available in the online version of the paper.
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ONLINE METHODS
Meta-analysis and combination of evidence across stages. Analyses were 
performed in each study (Supplementary Table 1a) to test the following com-
parisons: all CAD cases with all controls, adjusted for sex and age; male CAD 
cases with male controls, adjusted for age; female CAD cases with female 
controls, adjusted for age; early-onset CAD cases with early age of onset 
(≤50 years) with all CAD controls, adjusted for sex; late-onset CAD cases 
(>50 years) with all controls, adjusted for sex; and all myocardial infarction 
cases with all controls, adjusted for age and sex. Age was defined as the recruit-
ment age for controls and the event age for cases. We used the additive genetic 
model and fixed-effect inverse variance–weighted meta-analysis. SNPs were 
excluded from the meta-analysis if present in <17 GWAS and/or Metabochip 
or <13 Metabochip stage 2 studies. Heterogeneity was evaluated using the 
Cochran’s Q and I2 statistics. For SNPs with non-significant heterogeneity 
(P for Q > 0.01), we report fixed-effect model results. For SNPs with significant 
heterogeneity (P for Q <0.01), we performed an outlier test comparing the 
results in each study with the average of all other studies. For outliers (P < 0.01 
or no studies with data), we excluded the most extreme study and repeated 
the meta-analysis. If no outliers were detected, but heterogeneity was signifi-
cant, we used a random-effects model that was also used for all SNPs with 
significant heterogeneity in stage 1. In stage 3, we used a fixed-effect inverse 
variance–weighted meta-analysis.
The combination of evidence across stage 1 and stage 2 meta-analysis results 
was performed using Fisher’s combined P-values method; using two-sided 
P values from stage 1 and one-sided P values from stage 2 for all SNPs with 
consistent direction of effect across the two stages. We estimated the stage 1 and 
2 combined effect sizes for SNPs in the known loci using a fixed-effect inverse 
variance–weighted meta-analysis. The combination of evidence across stages 
1– 3 for the replication effort was performed using a sample size–weighted meta-
analysis for the selected SNPs. All participants gave written consent for partici-
pation in genetic studies, and the protocol of each study was approved by the 
corresponding local research ethics committee or institutional review board.
False discovery rate. FDR control is an alternative approach to experiment-
wise error rate control that allows for statistical multiple testing; identifying as 
many significantly associated SNPs as possible with a tolerable false positive 
burden. FDR analysis is useful for selecting extended panels of SNPs (and 
genes) for experiments on the basis of multiple signals (for example, pathway 
or network analyses) that are robust to contamination by a small number of 
false positive signals. However, given the specific design of the Metabochip 
array to include selected SNPs (for replication) with significant P values and 
several high-density regions (for fine mapping) associated with CAD and the 
other cardiometabolic traits, the number of SNPs significantly associated with 
CAD, as well as high LD, could bias the FDR analysis. Therefore, we excluded 
from the 79,138 SNPs with available stage 1 and 2 data all SNPs falling in a 
high-density region associated with CAD (Tables 1 and 2), as well as CAD 
risk SNPs associated at P < 5 × 10−8. Furthermore, we performed an LD-based 
SNP pruning of the remaining high-density regions (r2 < 0.2). In total, 54,806 
SNPs were included in the FDR analysis.
We combined stage 1 and 2 data as an inverse variance–weighted average, 
and P values were calculated by Wald test. SNPs selected because their stage 
1 P values were below 0.01 had their combined P values adjusted. If p0 is the 
P value used as the criterion for selection in stage 1, z12 is the standardized 
test statistic obtained by combining the stages (arbitrarily assumed to be posi-
tive) and s1 and s2 are the standard errors for the two stages, then the adjusted 
P value is the sum of two integrals representing the two tails in which the stage 
1 result might fall. The first is: 
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and the second has the same form but is integrated from − to Φ−1(p0/2), 
where Φ is the cumulative normal function. To test the adjusted P values, a 
simulation was performed in which null SNPs were generated and selected 
in stage 1 on the basis of their P values. These were combined with random 
second-stage data simulated again assuming a null effect. The adjusted P values 
had the expected uniform distribution between zero and one, suitable for use 
in the FDR analysis.
FDR analysis was performed using QVALUE software. A natural cubic 
spline (with 4 degrees of freedom) was fitted to provide a smoothed estimate 
of the proportion of null P values (pˆ0). A density histogram of the P values 
for the 54,806 SNPs is shown in Supplementary Figure 7. At FDR = 0.05, we 
obtained 138 SNPs that were combined with 73 independent SNPs from fine-
mapping regions associated with CAD. The selection included the SNP with 
the lowest combined P value per fine-mapping region and all SNPs within 
these regions that met the 5% FDR criterion in a separate analysis and were 
unlinked (r2 < 0.2). Finally, all SNPs reported in Tables 1 and 2 were added to 
the set of 211 SNPs (5% FDR results and CAD fine-mapped regions), resulting 
in 153 independent SNPs (104 identified through the FDR analysis) at r2 < 0.2, 
which were used for heritability calculations (Supplementary Table 9).
Heritability. Heritability estimates were calculated locus by locus using the 
multifactorial liability threshold model based on OR estimates that assume that 
the lead SNP at a locus accurately tags the disease-causing variant, as described 
in ref. 12. The calculations are based on a disease prevalence estimate of 5% 
and an estimate of 40% for the total heritability of coronary disease.
Expression analyses. We interrogated the 16 new (or proxy; r2 > 0.8) CAD 
risk SNPs for cis eQTL expression in multiple tissues: the ASAP study31 used 
tissue biopsies taken from patients undergoing carotid endartectomy (plaque 
n = 117) or valve surgery (liver n = 152, aorta media n = 117, aorta adventitia 
n = 103 and mammary artery n = 88). Expression data were generated using 
the Affymetrix HG-U133 plus 2.0 array (plaque) or the Affymetrix ST1.0 Exon 
array (liver, aorta and mammary artery); in the MuTHER study32, RNA levels 
were measured in LCLs (n = 826), skin (n = 705) and fat biopsies (n = 825) 
from 850 female twins (one-third monozygotic and two-thirds dizygotic) from 
the TwinsUK resource using the Illumina HumanHT-12v3 array. We assessed 
genotype with gene expression associations, using an additive linear model 
(within a 1-Mb window); in Cardiogenics5, monocytes and macrophages were 
collected from healthy subjects and individuals with CAD, and RNA was pro-
filed with the Illumina Human Ref-8 array. eQTL analysis was undertaken in 
459 healthy individuals from Cambridge, UK, using an additive linear model 
(1-Mb window); in the Massachusetts General Hospital study33 of liver, omen-
tum and subcutaneous adipose tissue among subjects undergoing Roux-en-Y 
gastric bypass surgery, eQTL analysis was performed with a linear regression 
model using a 1-Mb window.
In loci with significant cis-eQTL signal(s) (P < 1 × 10−4), we also identi-
fied the most strongly associated cis-eQTL SNP (eSNP) for the correspond-
ing transcript and then performed conditional analyses, including in the 
regression model, with either the lead eSNP or the lead CAD-associated SNP. 
On the basis of the conditional analysis, we determined whether the same 
variant underlies both gene expression regulation and disease.
Finally, we interrogated the lead SNPs in the 16 new CAD susceptibility loci 
for allelic expression imbalance effects in LCLs, fibroblasts and monocytes 
(n = 188; Cardiogenics), as described in ref. 34.
Network analysis. Genes for network analysis were selected using 310 SNPs 
(88 SNPs in known and new CAD risk loci and 222 SNPs at FDR <10% and LD 
pruned to r2 ≤ 0.7). We first selected genes with an eQTL (P ≤ 1 × 10−6) and 
then on the basis of physical proximity (included overlapping genes on oppo-
site strands or at equal distance from the SNP; genes were considered within a 
40-kb window centered on the SNP). Spliced ESTs and putative transcripts were 
not included. Network analysis was performed using the Ingenuity Pathway 
Analysis software tool (IPA; Ingenuity Systems). We considered molecules 
and/or relationships available in The IPA Knowledge Base for human, mouse 
or rat and set the confidence filter to experimentally observed or high (pre-
dicted). Networks were generated with a maximum size of 70 genes, allowing 
up to 10 networks. Molecules in the query set with recorded interactions were 
‘eligible’ for network construction using the IPA algorithm. Networks were 
ranked according to their degree of relevance to the eligible molecules in the 
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